Yoo BW, Kim CO, Izu A, Arora AK, Heijnen E. Phase 4, Post-Marketing Safety Surveillance of the MF59-Adjuvanted Influenza Vaccines FLUAD? and VANTAFLU? in South Korean Subjects Aged ≥65 Years. Infect Chemother. 2018 Dec;50(4):301-310
BACKGROUD:
Influenza vaccination is recommended for adults aged ≥65 years as they are at high risk of significant morbidity and mortality. This open-label, multicenter, post-marketing surveillance study assessed the safety of the MF59-adjuvanted trivalent inactivated subunit influenza vaccine, which is marketed as FLUAD? and VANTAFLU?, in South Korean subjects aged ≥65 years.
MATERIALS AND METHODS:
Solicited local and systemic adverse events (AEs) were collected from day 1 to 4 of the study. All unsolicited AEs and serious AEs (SAEs) were recorded from day 1 until study termination (day 29).
RESULTS:
Of the 770 subjects enrolled (FLUAD?, n = 389; VANTAFLU?, n = 381), 39% overall experienced any solicited AE. Local AEs were reported by 33% of subjects overall; with the most common events being injection-site pain (30%) and tenderness (27%). Systemic AEs were reported by 19% of subjects overall with the most common events being myalgia (11%) and fatigue (8%).
CONCLUSION:
These results show that the MF59-adjuvanted influenza vaccine known as FLUAD? or VANTAFLU? had acceptable safety profiles in older adults (aged ≥65 years) in South Korea.
Influenza vaccination is recommended for adults aged ≥65 years as they are at high risk of significant morbidity and mortality. This open-label, multicenter, post-marketing surveillance study assessed the safety of the MF59-adjuvanted trivalent inactivated subunit influenza vaccine, which is marketed as FLUAD? and VANTAFLU?, in South Korean subjects aged ≥65 years.
MATERIALS AND METHODS:
Solicited local and systemic adverse events (AEs) were collected from day 1 to 4 of the study. All unsolicited AEs and serious AEs (SAEs) were recorded from day 1 until study termination (day 29).
RESULTS:
Of the 770 subjects enrolled (FLUAD?, n = 389; VANTAFLU?, n = 381), 39% overall experienced any solicited AE. Local AEs were reported by 33% of subjects overall; with the most common events being injection-site pain (30%) and tenderness (27%). Systemic AEs were reported by 19% of subjects overall with the most common events being myalgia (11%) and fatigue (8%).
CONCLUSION:
These results show that the MF59-adjuvanted influenza vaccine known as FLUAD? or VANTAFLU? had acceptable safety profiles in older adults (aged ≥65 years) in South Korea.
See Also:
Latest articles in those days:
- Characterisation of a human monoclonal antibody targeting a conserved epitope at the base of the HA head of influenza A(H3N2) virus 6 hours ago
- An outbreak report of Influenza A(H3) among residents of a large nursing home in northern Italy: attack rates, clinical features and outcomes 19 hours ago
- Susceptibility of calves fed unpasteurized milk from cows infected with highly pathogenic avian influenza H5N1 19 hours ago
- Functional mapping of IFITM3 resolves its antiviral core and deciphers human influenza susceptibility 19 hours ago
- Comparison of the adjuvant effect of AS01, AS03 and alum on the immune response to GMP-grade H5N1 antigen in guinea pigs 2 days ago
[Go Top] [Close Window]
